Hematology
Article
Thrombocytopenia and neutropenia: A structured approach to evaluation
These algorithms and tables will help you quickly assess the severity of the 2 blood abnormalities and delineate between life-threatening and...
Article
Unravelling the CAR T-cell therapy reimbursement riddle
Article
CAR T-cell approvals: multiple myeloma likely next up
Article
Tumor heterogeneity: a central foe in the war on cancer
Article
The impact of inpatient rehabilitation on outcomes for patients with cancer
Outcomes Research in Review
Does Oral Chemotherapy Venetoclax Combined with Rituximab Improve Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia?
Latest News
MRD-negative status signals better outcomes in CAR T–treated ALL
CHICAGO – The study sheds light on the value of transplant after treatment with CAR T cells.
Outcomes Research in Review
CAR T-Cell Therapy Shows High Levels of Durable Response in Refractory Large B-Cell Lymphoma
News
Five-year survival for non-Hodgkin lymphoma tops 71%
The most advanced cases are the most likely to be diagnosed.
News
Coming soon: CAR T-cell approvals in multiple myeloma
CAR T-cell approvals for multiple myeloma are on the horizon and will transform oncology, according to Dr. Carl June.